(firstQuint)A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus.

 This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus.

 Each subject will be randomly allocated to a sequence of three treatments:(i) simultaneous administrations of BioChaperone(R) pramlintide human insulin (BC Pram Ins) and placebo, (ii) simultaneous injections of pramlintide (Symlin(R)) and human insulin (Humulin(R)) and (iii) simultaneous injections of insulin lispro (Humalog(R)) and placebo.

 Subjects will come in a fasted state to the clinical trial centre in the morning, meal test procedures will be performed and subjects will stay at the clinical trial centre until the post-dose follow-up period has been terminated.

.

 A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus@highlight

This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus.

